EA201492031A1 - Способы лечения диабетической ретинопатии и других офтальмологических заболеваний - Google Patents

Способы лечения диабетической ретинопатии и других офтальмологических заболеваний

Info

Publication number
EA201492031A1
EA201492031A1 EA201492031A EA201492031A EA201492031A1 EA 201492031 A1 EA201492031 A1 EA 201492031A1 EA 201492031 A EA201492031 A EA 201492031A EA 201492031 A EA201492031 A EA 201492031A EA 201492031 A1 EA201492031 A1 EA 201492031A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
patient
diabetic retinopathy
ophthalmological diseases
Prior art date
Application number
EA201492031A
Other languages
English (en)
Russian (ru)
Inventor
Клаес Олоф Бавик
Сюзан Хайес Генри
Рио Кубота
Владимир А. Кукса
Original Assignee
Эйкьюсела Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйкьюсела Инк. filed Critical Эйкьюсела Инк.
Publication of EA201492031A1 publication Critical patent/EA201492031A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
EA201492031A 2012-05-04 2013-05-03 Способы лечения диабетической ретинопатии и других офтальмологических заболеваний EA201492031A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643058P 2012-05-04 2012-05-04
US201261643178P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US201361781907P 2013-03-14 2013-03-14
PCT/US2013/039562 WO2013166449A2 (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Publications (1)

Publication Number Publication Date
EA201492031A1 true EA201492031A1 (ru) 2015-05-29

Family

ID=49515046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492031A EA201492031A1 (ru) 2012-05-04 2013-05-03 Способы лечения диабетической ретинопатии и других офтальмологических заболеваний

Country Status (18)

Country Link
US (4) US9957224B2 (enExample)
EP (2) EP2844636B1 (enExample)
JP (6) JP2015518491A (enExample)
KR (1) KR20150013240A (enExample)
CN (3) CN107865830A (enExample)
AU (1) AU2013256029A1 (enExample)
BR (1) BR112014027571B1 (enExample)
CA (1) CA2872433C (enExample)
EA (1) EA201492031A1 (enExample)
ES (1) ES2792923T3 (enExample)
HK (2) HK1203478A1 (enExample)
IL (1) IL235446A0 (enExample)
MX (2) MX2014013341A (enExample)
PH (1) PH12014502449A1 (enExample)
SG (1) SG11201407162SA (enExample)
TW (1) TW201406707A (enExample)
WO (1) WO2013166449A2 (enExample)
ZA (1) ZA201408592B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160052A (en) * 2007-10-05 2017-02-15 Acucela Inc Alkoxy compounds for disease treatment
EP2448569B1 (en) * 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
JP2015505536A (ja) 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
HK1217322A1 (zh) * 2013-03-12 2017-01-06 奥克塞拉有限公司 用於治疗眼科疾病和病症的取代的3-苯基丙胺衍生物
EP3195838B1 (en) 2013-03-14 2018-08-22 Optimedica Corporation Laser capsulovitreotomy
EP3129054B1 (en) * 2014-04-10 2020-12-09 Lankenau Institute for Medical Research Methods and compositions for the treatment of ocular diseases and disorders
WO2017062990A1 (en) * 2015-10-09 2017-04-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US11253489B2 (en) 2017-02-27 2022-02-22 Case Western Reserve University Visual cycle modulators
CN111526779B (zh) * 2017-12-28 2023-07-11 株式会社尼康 图像处理方法、图像处理程序、图像处理装置、图像显示装置、以及图像显示方法
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
US11624937B2 (en) 2018-07-07 2023-04-11 Acucela Inc. Device to prevent retinal hypoxia
EP3830636A4 (en) 2018-07-30 2022-04-13 Acucela Inc. OPTICAL DESIGNS OF AN ELECTRONIC CONTACT LENS TO REDUCE MYOPIA PROGRESSION
CN112888440A (zh) * 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
CA3116577A1 (en) * 2018-10-19 2020-04-23 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
JPWO2020240867A1 (enExample) * 2019-05-31 2020-12-03
CN114502120B (zh) 2019-07-31 2025-11-28 奥克塞拉有限公司 用于将图像投射到视网膜上的设备
JP2022547621A (ja) 2019-09-16 2022-11-14 アキュセラ インコーポレイテッド 近視の進行を阻害するように設計される、電子ソフトコンタクトレンズのための組立プロセス
CN115336113A (zh) 2020-02-21 2022-11-11 奥克塞拉有限公司 用于电子隐形眼镜的充电盒
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
KR20230003191A (ko) 2020-05-13 2023-01-05 어큐셀라 인코포레이티드 근시 치료를 위한 전자식 스위칭 가능한 안경
JP2023529875A (ja) 2020-06-08 2023-07-12 アキュセラ インコーポレイテッド 非点収差を治療するための非対称投影を伴うレンズ
EP4161636A4 (en) 2020-06-08 2024-06-26 Acucela Inc. Projection of defocused images on the peripheral retina to treat refractive error
EP4162316A4 (en) 2020-06-08 2024-10-23 Acucela Inc. Stick on devices using peripheral defocus to treat progressive refractive error
US11281022B2 (en) 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
AU2022278549A1 (en) * 2021-05-16 2023-12-07 Metanoia Bio Inc. Methods and compositions for treating ocular neovascular disease
WO2022255332A1 (ja) * 2021-06-03 2022-12-08 国立大学法人大阪大学 未熟児網膜症スクリーニング方法、スクリーニング装置及び学習済モデル
US20240408056A1 (en) * 2023-06-12 2024-12-12 Synaptogenix, Inc. Methods for repairing nerve damage using pkc activating therapeutic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP2005511576A (ja) * 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
WO2005087210A2 (en) * 2004-03-17 2005-09-22 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
KR101368248B1 (ko) 2007-04-20 2014-03-14 어큐셀라 인코포레이티드 안과 질환 및 장애 치료용 스티레닐 유도체 화합물
NZ601866A (en) * 2007-06-29 2013-12-20 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
MY160052A (en) * 2007-10-05 2017-02-15 Acucela Inc Alkoxy compounds for disease treatment
KR20130012969A (ko) 2007-11-01 2013-02-05 어큐셀라 인코포레이티드 안과 질환 및 장애를 치료하기 위한 아민 유도체 화합물
NZ592057A (en) 2008-09-05 2013-01-25 Acucela Inc Sulfur-linked compounds for treating opthalmic diseases and disorders
AU2009308483C1 (en) * 2008-10-22 2014-01-23 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
EP2448569B1 (en) 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Also Published As

Publication number Publication date
IL235446A0 (en) 2014-12-31
US9957224B2 (en) 2018-05-01
HK1203478A1 (en) 2015-10-30
JP2023059991A (ja) 2023-04-27
JP2018024702A (ja) 2018-02-15
CA2872433A1 (en) 2013-11-07
ZA201408592B (en) 2017-09-27
PH12014502449A1 (en) 2015-01-12
JP2020023535A (ja) 2020-02-13
US11795136B2 (en) 2023-10-24
US20180346407A1 (en) 2018-12-06
EP2844636A2 (en) 2015-03-11
JP2025069362A (ja) 2025-04-30
WO2013166449A3 (en) 2014-01-30
CN116850163A (zh) 2023-10-10
CA2872433C (en) 2022-06-28
MX2020001835A (es) 2021-09-09
JP2021075576A (ja) 2021-05-20
US10730825B2 (en) 2020-08-04
CN107865830A (zh) 2018-04-03
MX386024B (es) 2025-03-18
AU2013256029A1 (en) 2014-12-04
ES2792923T3 (es) 2020-11-12
BR112014027571A2 (pt) 2017-07-18
MX2014013341A (es) 2015-06-02
SG11201407162SA (en) 2014-11-27
JP2015518491A (ja) 2015-07-02
BR112014027571B1 (pt) 2021-08-31
EP2844636A4 (en) 2016-03-09
US20140039048A1 (en) 2014-02-06
US20210171435A1 (en) 2021-06-10
HK1246646A1 (zh) 2018-09-14
EP3741742A1 (en) 2020-11-25
TW201406707A (zh) 2014-02-16
US20240308951A1 (en) 2024-09-19
WO2013166449A2 (en) 2013-11-07
KR20150013240A (ko) 2015-02-04
EP2844636B1 (en) 2020-04-22
CN104411678A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
EA201100654A1 (ru) Соединения для лечения офтальмологических заболеваний и расстройств
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2015007931A (es) Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
AU2016219703A1 (en) Methods for treating and diagnosing blinding eye diseases
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112014008759A2 (pt) tratamento de doença ocular
MX350378B (es) Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
EA200970944A1 (ru) Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
MX2015005038A (es) Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291